Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

BACKGROUND: Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assist in the development of BACE1 inhibitors, we report detailed safety findings fr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Alzheimers Res Ther
Asıl Yazarlar: Egan, Michael F., Mukai, Yuki, Voss, Tiffini, Kost, James, Stone, Julie, Furtek, Christine, Mahoney, Erin, Cummings, Jeffrey L., Tariot, Pierre N., Aisen, Paul S., Vellas, Bruno, Lines, Christopher, Michelson, David
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6685277/
https://ncbi.nlm.nih.gov/pubmed/31387606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-019-0520-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller